Assessment of clinical studies evaluating combinations of immune checkpoint inhibitors with locoregional treatments in solid tumors |
| |
| Institution: | 1. Department of Oncology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Turin, Italy;2. Oncology Unit, ASST Bergamo Ovest, Treviglio, Bergamo, Italy;3. Department of Radiology, University of Cagliari, Cagliari, Italy;4. Harvard Premedical Program, Harvard University, Cambridge, MA, USA;5. Medical Oncology, Hospital of Nuoro, ASSL Nuoro, Nuoro, Italy;6. Department of Medical Oncology, Azienda Ospedaliera Universitaria Di Cagliari, Cagliari, Italy;1. Institute of Medical Immunology, Affiliated Hospital of Jiangsu University, Zhenjiang, China;2. Department of Laboratory Medicine, Affiliated Hospital of Jiangsu University, Zhenjiang, China;3. Department of Rheumatology, the Second People''s Hospital, China Three Gorges University, Yichang, China;4. Department of Rheumatology and immunology, Xiangya Hospital, Central South University, Changsha, China;5. Department of Pathology and Shenzhen Institute of Research and Innovation, The University of Hong Kong; Chongqing International Institute for Immunology, China;6. Department of Gastrointestinal Surgery, Affiliated Hospital of Jiangsu University, Zhenjiang, China;7. Department of Immunology, Jiangsu Key Laboratory of Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, China;1. Institut de Génétique Humaine, Univ Montpellier, CNRS, Montpellier, France;2. Aarhus University, Department of Biomedicine, Aarhus, Denmark;1. School of Graduate, Shaanxi University of Chinese Medicine, No. 1 Middle section of Shiji Avenue, Xianyang 712046, China;2. Department of Cardiology, Shaanxi Provincial Hospital of Chinese Medicine, No.4 Xihuamen Street, Xi''an 710003, China;3. Department of Emergency, Xiyuan Hospital, China Academy of Chinese Medical Sciences, No.1 Xiyuan Playground Street, Beijing 100091, China;4. School of Basic Medicine, Fourth Military Medical University, No. 169 Changle West Rd, Xi’an 710032, China;5. Real World Clinical Research Institute, Shaanxi University of Chinese Medicine, No. 1 Middle section of Shiji Avenue, Xianyang 712046, China;1. Institute of Cerebrovascular Disease Research, Xuanwu Hospital of Capital Medical University, Beijing 100053, China;2. Beijing Geriatric Medical Research Center, Beijing 100053, China;3. Department of Neurology, Beijing Luhe Hospital, Capital Medical University, Beijing 101149, China |
| |
| Abstract: | In the last decade, immunotherapy with immune checkpoint inhibitors (ICIs) has changed the therapeutic algorithm of cancer patients. ICIs combined with other therapeutic options, such as chemo- and targeted therapies, generate impressive results in cancer patients. Locoregional treatments (LRTs) play an important role in the management of various solid tumors (e.g., hepatocellular carcinoma (HCC), neuroendocrine tumors, etc.), and this therapeutic approach may enhance the activity of the immune response to tumor cells destroying primary tumors and leading to the release of several soluble molecules. This systematic review was performed to identify studies reporting objective response rate (ORR) and survival information in patients with solid tumors treated with ICIs plus LRTs. In the present work, fourteen studies were included, and the majority of them (five studies) enrolled patients with hepatocellular carcinoma (HCC), whereas the others included patients with different diseases. The highest ORRs were seen in HCC (67%, Y-90 RE plus ipilimumab and nivolumab) and melanoma (38%, dendritic cells with mRNA plus ipilimumab) patients. ORRs were not observed in liver metastases from melanoma and colorectal cancer. These data suggest that combination of ICIs and LRTs is feasible and more active in primary tumors (particularly HCC) than metastases with a synergistic effect on antitumor immunity. However, further studies are needed to better select patients, schedules, and setting of treatments. |
| |
| Keywords: | Locoregional treatments Immune checkpoint inhibitors Solid tumors |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
